Today, Cerus announced that its second quarter 2024 financial results will be released on Thursday, August 1, 2024. You can read the full press release here: https://ow.ly/fOxs50SFp2R
Cerus
Biotechnology Research
Concord, California 9,188 followers
At Cerus, we are proud of our consistent and unwavering focus to secure blood safety around the globe.
About us
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
- Website
-
http://www.cerus.com
External link for Cerus
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Concord, California
- Type
- Public Company
- Founded
- 1992
- Specialties
- blood safety, pathogen inactivation, hospital safety, patient safety, pandemic preparedness, plasma, pathogen reduction, blood supply, healthcare, public health, transfusion medicine, platelets, and bleeding
Locations
-
Primary
1220 Concord Ave
Suite 600
Concord, California 94520, US
-
Stationsstraat 79-D
3811 MH Amersfoort, NL
Employees at Cerus
Updates
-
While fibrinogen is generally recognized as a critical blood clotting factor that can decline quickly in the massive hemorrhage patient, logistical challenges often prevent its rapid administration. Earlier this month, the American Journal of Clinical Pathology published the experience of Dr. Sethapati et al. with the implementation of pathogen reduced cryoprecipitated fibrinogen complex (commonly referred to as INTERCEPT Fibrinogen Complex) at Stanford Health Care’s Blood Bank. The publication, which details the positive impact of this blood product on waste and turnaround time at a single site, can be found here: https://ow.ly/HBIp50SAsrU #massivehemorrhage #transfusion #fibrinogen
-
We are delighted to announce the appointment of Dean Gregory to the Cerus Board of Directors. You can read the full press release here: https://ow.ly/snF250Su8Og
-
-
Cerus would like to welcome and congratulate our June new hire: Rose Tomey. We’re excited to have you join us and anticipate all your contributions, Rose!
-
-
Today, Cerus Corporation announced our symposium and abstracts at the 38th International Congress of the International Society of Blood Transfusion. You can read the full press release here: https://ow.ly/S6zP50SnfqS #ISBT
-
-
Summer of Giving runs from Tuesday, May 28, 2024, through National Blood Donation Day on Wednesday, September 4, 2024, this initiative encourages businesses to host blood drives and all eligible individuals to donate blood in recognition of recent eligibility changes that promote fairness and inclusivity in the donation process while maintaining the safety of the blood supply. https://lnkd.in/gRB5wuKC #pridemonth #LGBTQ
Summer of Giving | GLAAD
https://glaad.org
-
Every day, the Cerus team is focused on safeguarding the global supply, so #WorldBloodDonorDay holds a special significance for us. Last week, we hosted an on-site blood drive at our U.S. headquarters, and true to form, turnout was amazing. Thank you to all our employees – including blood donors (Monique Ono, MPH, Rhonda Walker, Scott Seidenverg, Sebastian Nosker, Zach Ehrenberg, Tracey Diaz, Chrystal Menard, Michelle Gatmaitan, Michelle Payton, Jovita Villavicencio, Marc Stern, Brittany Dillon, Julie Yi, and Peter Bringmann) – for your continued passion for ensuring blood is safe and available – whether through your daily work or your life-saving blood donation. #WBDD #WorldBloodDonorDay #transfusion #bloodsafety #blooddonation
-
-
-
-
-
+8
-
-
Today, Cerus celebrates World Blood Donor Day 2024. You can read the full press release here: https://ow.ly/B5nY50SiSWO
-
-
Cerus is proud to join more than 80 partner organizations in support of Blood Advocacy Week, an important initiative by America’s Blood Centers to address critical issues facing our nation’s blood supply. JOIN THE MISSION: · Federal funding to support blood centers’ local education and awareness efforts. · Examine pre-hospital blood use for traumatic injuries. · Pilot initiatives to attract diverse and younger blood donors. · Reimburse palliative blood transfusions. WHY WE MUST ACT: Blood donations, especially those from school and business-based drives, have not recovered from the COVID-19 pandemic. The resulting decline in donors, particularly minority donors, is exacerbated by an aging population. In the U.S. every two seconds someone needs a blood transfusion, yet only a fraction of those who are eligible actually donate. Let’s come together to ensure a robust and equitable blood supply for all. #BloodAdvocacyWeek #Cerus #DonateBlood #SaveLives”
-
Affiliated pages
Similar pages
Browse jobs
Stock
CERS
NASDAQ
20 minutes delay
$2.20
-0.01 (-0.453%)
- Open
- 2.24
- Low
- 2.17
- High
- 2.25
Data from Refinitiv
See more info on